International Cancer Research Conference
March 24-26, 2025 | Singapore
Cancer Metabolomics
Metabolomics is the worldwide assessment and confirmation of endogenous small-molecule biochemicals (metabolites) within a biologic system. It is one of the "omic" sciences in systems biology. The metabolism of cancer cells is dysregulated to meet the demands of uncontrolled proliferation. This rewiring of cellular metabolism produces distinct metabolic phenotypes that can be exploited for earlier cancer detection, patient selection techniques for clinical trials, and/or treatment response biomarkers. Metabolomics aims to use cancer’s metabolic signature to estimate disease risk, detect cancer earlier, diagnose particular disease subtypes, and track treatment outcomes. In principle, metabolomics could aid in the rational selection of targeted medicines to meet cancer’s metabolic requirements.
- Cancer Cell Metabolism
- Cancer Therapies That Target Metabolism
- Systemic Metabolic Effects of Cancer
- Clinical Implementation of Metabolomics
- Biomarkers for Cancer
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Jianhua Luo
University of Pittsburgh, United States
Kaushala Prasad Mishra
Asian Association for Radiation Research (AARR), India
Mariola Wioletta Borowska
Maria Sklodowska-Curie National Research Institute of Oncology, Poland
Ibrahim El Bayoumy
Tanta faculty of medicine, Kuwait
Andrea González Báez
Autonomous University of Nuevo Leon, MexicoSubmit your abstract Today
Title :
Pietro Salvatori, Private Practice, Italy
Title :
Jianhua Luo, University of Pittsburgh, United States
Title :
Marika Crohns, Sanofi, Germany
Title : RNA binding proteins in the pathogenesis of pediatric cancer
Atif A Ahmed, University of Washington-Seattle Children’s Hospital, United States
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : The future of pharmacogenetic polymorphism, pharmacogenomics and pharmamicrobiome in cancer treatment
Bene Ekine-Afolabi, University of East London, United Kingdom